JP2011522774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522774A5 JP2011522774A5 JP2010543192A JP2010543192A JP2011522774A5 JP 2011522774 A5 JP2011522774 A5 JP 2011522774A5 JP 2010543192 A JP2010543192 A JP 2010543192A JP 2010543192 A JP2010543192 A JP 2010543192A JP 2011522774 A5 JP2011522774 A5 JP 2011522774A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- group
- compound
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 230000036407 pain Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000035619 diuresis Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- RQQOBMFXZYYQHN-UHFFFAOYSA-N [TlH2]C(C1=CNCN1)c1ccccc1 Chemical compound [TlH2]C(C1=CNCN1)c1ccccc1 RQQOBMFXZYYQHN-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2214808P | 2008-01-18 | 2008-01-18 | |
| US61/022,148 | 2008-01-18 | ||
| PCT/US2009/030849 WO2009091735A1 (en) | 2008-01-18 | 2009-01-13 | Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011522774A JP2011522774A (ja) | 2011-08-04 |
| JP2011522774A5 true JP2011522774A5 (enExample) | 2012-03-01 |
| JP5453312B2 JP5453312B2 (ja) | 2014-03-26 |
Family
ID=40592075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543192A Expired - Fee Related JP5453312B2 (ja) | 2008-01-18 | 2009-01-13 | アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択性モジュレーターである置換アリール‐（イミダゾール）‐メチル）‐フェニル化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8227499B2 (enExample) |
| EP (1) | EP2250153B1 (enExample) |
| JP (1) | JP5453312B2 (enExample) |
| AU (1) | AU2009205539B2 (enExample) |
| BR (1) | BRPI0906927A2 (enExample) |
| CA (1) | CA2712256A1 (enExample) |
| DK (1) | DK2250153T3 (enExample) |
| ES (1) | ES2421896T3 (enExample) |
| WO (1) | WO2009091735A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| US9290476B2 (en) | 2012-10-16 | 2016-03-22 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
| CN104884448A (zh) | 2012-10-16 | 2015-09-02 | 詹森药业有限公司 | Rorγt的杂芳基连接的喹啉基调节剂 |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| BR112016008258A2 (pt) | 2013-10-15 | 2017-10-10 | Janssen Pharmaceutica Nv | moduladores de ror?t de quinolinila |
| BR112016008215A2 (pt) | 2013-10-15 | 2017-09-26 | Janssen Pharmaceutica Nv | moduladores de quinolinila ligados por alquila de roryt |
| JP2019517524A (ja) * | 2016-06-02 | 2019-06-24 | パーデュー ファーマ エルピー | 疼痛治療のための微量アミン関連受容体１アゴニスト及び部分アゴニスト |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR206507A1 (es) | 1972-10-13 | 1976-07-30 | Ciba Geigy Ag | Procedimiento para la obtencion de nuevos 4-eteres de acidos 3-amino-5-sulfamoilbenzoicos |
| GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| US4661508A (en) * | 1984-06-18 | 1987-04-28 | Eli Lilly And Company | Aromatase inhibiting α,α-diphenyl-4(5)imidazole-methanes or -ethanes |
| CA1238640A (en) * | 1984-06-18 | 1988-06-28 | Kenneth S. Hirsch | 4(5)-substituted imidazoles |
| EP0762877B1 (en) * | 1994-06-03 | 2001-03-21 | THEJMDE Trust | Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof |
| PL341009A1 (en) * | 1997-12-04 | 2001-03-12 | Allergan Sales | Substitute derivatives of imidazole exhibiting agonist-like activity in respect to adrenergic alpha 2b or 2b/2c receptors |
| TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| RU2008130448A (ru) | 2006-01-27 | 2010-03-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | Применение производных 4-имидазола для расстройств цнс |
| RU2478631C2 (ru) * | 2007-05-14 | 2013-04-10 | Аллерган, Инк. | Соединения ((фенил)имидазолил)метилгетероарила, их применение, фармацевтическая композиция, содержащая указанные соединения, и набор, включающий такую композицию |
-
2009
- 2009-01-13 AU AU2009205539A patent/AU2009205539B2/en not_active Ceased
- 2009-01-13 CA CA2712256A patent/CA2712256A1/en not_active Abandoned
- 2009-01-13 WO PCT/US2009/030849 patent/WO2009091735A1/en not_active Ceased
- 2009-01-13 DK DK09702950.8T patent/DK2250153T3/da active
- 2009-01-13 BR BRPI0906927-5A patent/BRPI0906927A2/pt not_active IP Right Cessation
- 2009-01-13 EP EP09702950.8A patent/EP2250153B1/en not_active Not-in-force
- 2009-01-13 US US12/863,403 patent/US8227499B2/en not_active Expired - Fee Related
- 2009-01-13 JP JP2010543192A patent/JP5453312B2/ja not_active Expired - Fee Related
- 2009-01-13 ES ES09702950T patent/ES2421896T3/es active Active
-
2012
- 2012-04-24 US US13/454,259 patent/US20120202865A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522774A5 (enExample) | ||
| JP2011509297A5 (enExample) | ||
| JP2007516941A5 (enExample) | ||
| JP2008526888A5 (enExample) | ||
| CN1305856C (zh) | 合成伊伐布雷定及其与药学上可接受的酸的加成盐的新方法 | |
| JP2004517852A5 (enExample) | ||
| JP2005521671A5 (enExample) | ||
| JP2017524005A5 (enExample) | ||
| JP2015531764A5 (enExample) | ||
| JP2019532079A5 (enExample) | ||
| JP2009514835A5 (enExample) | ||
| JP2014502982A5 (enExample) | ||
| JP2002523491A5 (enExample) | ||
| JP2008524262A5 (enExample) | ||
| JP2004519438A5 (enExample) | ||
| CA2529320A1 (en) | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases | |
| JP2019512469A5 (enExample) | ||
| JP2009514836A5 (enExample) | ||
| JP2004505085A5 (enExample) | ||
| JP2011516417A5 (enExample) | ||
| JP2002523508A5 (enExample) | ||
| JP2017509676A5 (enExample) | ||
| RU2008108219A (ru) | Соединения, представляющие собой 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенный пиридин, для лечения неврологических, психиатрических или болевыхрасстройств | |
| CN1293673A (zh) | 用作nmda受体拮抗剂的1－(3－杂芳基丙基－或－丙－2－烯基)－4－苄基哌啶 | |
| JP2011521962A5 (enExample) |